![]() “We will consider additional actions to prevent non-medical use and identify efforts to better understand and strengthen the supply chain. “The lack of availability of certain medications in recent months has been understandably frustrating for patients and their families,” Califf and Milgram wrote in their letter. Estimated recovery dates range from this summer to December. The listed reasons for the shortages include “demand increase,” “shortage of active ingredient” or no reason at all. ![]() The FDA tracks the manufacturers that have reported shortages of prescription stimulants on its website. Sanjay Gupta every Tuesday from the CNN Health team.Ī report published this year by the US Centers for Disease Control and Prevention highlighted a surge in demand for prescription stimulants during the Covid-19 pandemic, especially among adults. Sign up here to get The Results Are In with Dr. The letter also highlights “widespread misuse” of prescription stimulant drugs and calls for “accelerate(d) efforts to support appropriate diagnosis and treatment of ADHD,” including more robust clinical guidelines for diagnosing ADHD in adults and alternative treatment options. The DEA says it is “committed to reviewing and improving” the quota process but asks that manufacturers relinquish any quota they can’t meet so it can be redistributed. And there’s a “similar trend” this year, according to the letter. But an internal analysis suggests that manufacturers fell 30% short of the full quota in 2022, leaving about 1 billion potential doses on the table. ![]() Stimulants are controlled substances, and the DEA does set limits on the amount that can be produced. ![]() “That said, we are working closely with numerous manufacturers, agencies, and others in the supply chain to understand, prevent, and reduce the impact of these shortages.”Ī surge in prescriptions for stimulant drugs in recent years, coupled with the residual effects of manufacturing delays that one key drugmaker experienced last fall, are among the “many factors” contributing to the shortage, they wrote. Robert Califf and Drug Enforcement Administration leader Anne Milgram wrote in a joint letter Tuesday. “The FDA and DEA do not manufacture drugs and cannot require a pharmaceutical company to make a drug, make more of a drug, or change the distribution of a drug,” FDA Commissioner Dr. Over the shoulder, female scientist using a micro-pipette to prepare samples in a fume hood Assembly/Stone RF/Getty Imagesĭrug shortages’ effects on cancer research may be felt for years to come ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |